Shionogi HIV trial shows 89% prefer injectable treatment

Shionogi announced results from the VOLITION trial showing 89% of HIV patients preferred switching from daily oral Dovato to long-acting injectable Cabenuva.

Key reasons included not worrying about forgetting doses (80%) and not needing to carry medication (68%).